Xcout Intel
AbolerIS Pharma
AbolerIS Pharma is a pre-clinical stage biotech company founded in Nantes, France, specializing in the development of innovative immunomodulators and advanced biopharmaceuticals for autoimmune conditions.
Subscribe to see AbolerIS Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AbolerIS Pharma at a glance
AbolerIS Pharma is a biotechnology company headquartered in France. It has raised at least $32M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $29M in September 2023. Xcout tracks 9 named people at AbolerIS Pharma, including Ann Meulemans (CEO).
AbolerIS Pharma leadership
- Ann MeulemansCEO
- Tomas Van DyckCFO
- Philippe AlenChief Business Officer (ad intrim)
- Ronald Van BremptCMO
- Carole GuillonneauCo-Founder
- F.-Xavier HubertDr. F.-Xavier Hubert, MD, PhD
3 more named people on record for AbolerIS Pharma, with roles, board committees and tenure — see the full roster →
AbolerIS Pharma funding rounds
At least $32M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $29M | 9 named | |
| — | $3M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
AbolerIS Pharma competitors
A few of AbolerIS Pharma's closest competitors — see the full list of competitors and alternatives →
Canopy Immuno-Therapeutics is a pre-clinical stage biotechnology company based in Haifa, Israel, focused on developing non-immunosuppressive biologics, including Antigen-Drug Conjugates, for antibody-mediated autoimmune conditions.
Polyneuron Pharmaceuticals is a venture-backed biotech and life sciences company headquartered in Basel, Switzerland. Founded in 2014, the company is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated autoimmune diseases.
AviSia Therapeutics is a clinical-stage biotechnology company headquartered in Amsterdam, Netherlands, pioneering antigen-specific immunotherapies for autoimmune diseases. Established as a spin-off, the company develops targeted treatments to reprogram immune responses.
Grey Wolf Therapeutics is a biotechnology company headquartered in the UK focused on delivering a new class of treatments to improve the lives of people with cancers and autoimmune disorders.
Get AbolerIS Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on AbolerIS Pharma in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access